TP53 and acute myeloid leukemia: Among six AML cell lines (3 with mutated, 3 with wildtype TP53) treated with DAC and ATRA, single-agent activity upon cell growth inhibition was variable (with notable ATRA sensitivity of the three cell lines with MLL rearrangements), without antagonistic effects (Fig. 1A, B).